Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The Adverse Outcome Pathway (AOP) concept leverages existing data to formalize and disseminate knowledge and is a well-accepted concept in chemical risk assessment. However, it does not handle the socio-economic impact that environmentally-induced diseases may generate, which might be highly relevant for risk management and prioritization. Here, we propose to connect the AOP framework by bridging an Adverse Outcome (AO) to Cost Outcomes (CO) creating so-called Cost Outcome Pathways (COPs) for including the socio-economic costs of exposure to chemicals into the AOP framework. Exposures to certain classes of chemicals have been linked to loss of intellectual quotient (IQ) points in children. This may lead to healthcare costs and reduced working productivity and contribute to increasing the substantial socio-economic burden worldwide. As an in silico case study, a new COP related to neurodevelopmental toxicity was designed, with a connection between the AO 'decreased, IQ' and an umbrella CO 'increased, socio-economic burden'. This framework can support policymaking in the public health sector and might also hold great potential for other environmental exposure-related diseases such as cancer, obesity or neurodegeneration, which are diseases known to have detrimental socio-economic impacts.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tox.2025.154225DOI Listing

Publication Analysis

Top Keywords

adverse outcome
12
cost outcome
8
outcome pathway
8
socio-economic impacts
8
outcome pathways
8
aop framework
8
socio-economic
6
framework
4
pathway framework
4
framework integrating
4

Similar Publications

Two expert reports of medical malpractice cases, in one of which there was a conclusion about the presence of a direct causal relationship with the natural course of the disease, and the other - with the incorrect actions of the doctor, were analyzed. Methodological approaches to solving such issues are discussed. It is recommended to use the logical method of hypothetical elimination of incorrect actions of medical professionals in order to avoid errors.

View Article and Find Full Text PDF

To analyze in-hospital mortality in children undergoing congenital heart interventions in the only public referral center in Amazonas, North Brazil, between 2014 and 2022. This retrospective cohort study included 1041 patients undergoing cardiac interventions for congenital heart disease, of whom 135 died during hospitalization. Records were reviewed to obtain demographic, clinical, and surgical data.

View Article and Find Full Text PDF

BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.

View Article and Find Full Text PDF

Importance: Cannabis is the most commonly used illicit drug, with 10% to 30% of regular users developing cannabis use disorder (CUD), a condition linked to altered hippocampal integrity. Evidence suggests high-intensity interval training (HIIT) enhances hippocampal structure and function, with this form of physical exercise potentially mitigating CUD-related cognitive and mental health impairments.

Objective: To determine the impact of a 12-week HIIT intervention on hippocampal integrity (ie, structure, connectivity, biochemistry) compared with 12 weeks of strength and resistance (SR) training in CUD.

View Article and Find Full Text PDF

Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.

Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.

View Article and Find Full Text PDF